REG - Hikma Pharmaceutical - Director changes and update on AGM 2022 resolution

Hikma PharmaceuticalsAnnouncement

30/09/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220930:nRSd2364Ba&default-theme=true

RNS Number : 2364B  Hikma Pharmaceuticals Plc  30 September 2022

Director changes and update on AGM 2022 resolution

 

 

Hikma appoints Victoria Hull and Laura Balan as Directors

 

London, 30 September 2022 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK)
(Hikma) announces the appointments of Laura Balan and Victoria Hull as
independent Non-Executive Directors with effect from 1 October and 1 November
2022 respectively.

 

Commenting on their appointments, Said Darwazah, Executive Chairman and CEO
said 'I am very pleased to welcome Laura and Victoria to the Hikma Board.
Laura brings extensive knowledge of the global healthcare industry and an
excellent track record of investing in a broad range of healthcare
businesses.  She is a strong strategic thinker who will add value to the
Board. Victoria brings broad experience across a range of businesses, having
held executive and non-executive director roles. She has strong experience of
the UK listed environment and brings extensive M&A experience to the
Board".

 

In line with our plans for the future composition of the Hikma Board, Victoria
will be appointed Senior Independent Director and assume the role of Chair of
the Nomination and Governance Committee during the course of 2023. The
effective date for these changes will be confirmed in the 2022 Annual Report.

 

About Laura Balan

Laura worked for 17 years at The Capital Group Companies, the US investment
manager with $2.6 trillion under management, where she recently retired from
her role as partner. Covering the European healthcare and pharmaceutical
sectors while at Capital, Laura gained a deep understanding of international
business, the pharmaceutical industry globally, key sector trends and
dynamics. Prior to her time at Capital, she held associate and analyst roles
at The Goldman Sachs Group Inc, focused on European healthcare and global
investment research.

 

Laura in an investment professional and CFA Charterholder, she holds an
BA(Hons) in International Business from the Bucharest Academy of Economic
Studies.

 

About Victoria Hull

An experienced non-executive director, Victoria is currently serving
Non-Executive Directorships and Remuneration Committee Chair positions for IQE
PLC, Alphawave IP Group PLC and Network International Holdings PLC. Victoria
was also the Senior Independent Director for Ultra Electronics Holdings PLC,
until their acquisition by a private equity firm in August 2022.

 

During her executive career, Victoria was Chief Legal Officer and Executive
Director at Invensys Plc, now Schneider Electric, from 2001 to 2014. Prior to
this, she held various roles at Telewest Communications PLC from 1994 to 2001,
including Executive Director and Chief Legal Officer & Company Secretary.
Victoria is a solicitor and began her career at Clifford Chance LLP.

 

 

Update on AGM 2022 resolution

 

In accordance with the requirement of Provision 4 of the UK Corporate
Governance Code, Hikma is providing an update following significant votes
(defined as above 20%) against resolution 8 for the re-election of Pat Butler,
Senior Independent Director and Chair of the Nomination and Governance
Committee at the Annual General Meeting held on 25 April 2022 ("2022 AGM").

 

Following feedback from shareholders prior to the 2022 AGM, the Board
understood that the level of significant votes against resolution 8 was
because the level of female representation on the Board fell from 30% to 22%
at the conclusion of the 2022 AGM, significantly below the gender diversity
target set by the Hampton-Alexander Review. The reduction in female
representation followed the retirement of Dr. Pamela Kirby at the 2022 AGM,
which the Board had previously envisaged would happen in 2023.

 

The Board has always taken diversity seriously, having adopted the diversity
targets set by the Hampton-Alexander Review and the Parker Review, and,
assisted by its Nomination and Governance Committee, immediately took steps
following the 2022 AGM to raise the level of female representation on the
Board.

 

The appointments of Laura Balan and Victoria Hull as independent Non-Executive
Directors with effect from 1 October and 1 November 2022, respectively, bring
the level of female representation on our Board to 40%, in line with the new
gender diversity target set by the Listing Rules and ahead of the FCA's
implementation timetable for financial years beginning on or after 1 April
2022.

 

A further update will be provided in the 2022 Annual Report.

 

 

-- ENDS --

 

Enquiries:

 

Hikma Pharmaceuticals PLC

Hussein Arkhagha, Chief Counsel and Company
Secretary
+44 (0)20 7399 2760

Susan Ringdal, EVP Strategic Planning and Global Affairs
                        +44 (0)20 7399 2760

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOALLMFTMTBTBFT